We show that DCK is a critical determinant of sensitivity to treatment with gemcitabine alone or in combination with entinostat in pancreatic cancer cells, demonstrating the ability of this system to reveal the critical mediators of response to cancer therapeutics. Here, DCK is linked to pancreatic neoplasm.